78 related articles for article (PubMed ID: 643899)
1. Stimulation of "regulatory" dopamine receptors by bromocriptine (CB-154).
Di Chiara G; Porceddu ML; Vargiu L; Gessa GL
Pharmacology; 1978; 16 Suppl 1():135-42. PubMed ID: 643899
[TBL] [Abstract][Full Text] [Related]
2. Evidence for selective and long-lasting stimulation of "regulatory" dopamine-receptors by bromocriptine (CB 154).
di Chiara G; Porceddu ML; Vargiu L; Stefanini E; Gessa GL
Naunyn Schmiedebergs Arch Pharmacol; 1977 Nov; 300(3):239-45. PubMed ID: 600311
[TBL] [Abstract][Full Text] [Related]
3. Bromocriptine: a rather specific stimulant of dopamine receptors regulating dopamine metabolism.
Di Chiara G; Vargiu L; Porceddu ML; Gessa GL
Adv Biochem Psychopharmacol; 1977; 16():443-6. PubMed ID: 578073
[No Abstract] [Full Text] [Related]
4. Combined administration of direct dopamine receptor agonists and L-dopa does not interfere with utilization of exogenous L-dopa in rat corpus striatum.
Globus M; Melamed E
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):211-5. PubMed ID: 6310691
[TBL] [Abstract][Full Text] [Related]
5. Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine.
Jackson DM; Martin LP; Larsson LG; Cox RF; Waszczak BL; Ross SB
Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep; 342(3):290-9. PubMed ID: 2126347
[TBL] [Abstract][Full Text] [Related]
6. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
7. Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats.
Kenny AM; Schneider MB; Baden DR; Pfeiffer RF; Murrin LC
Neurology; 1986 Mar; 36(3):400-4. PubMed ID: 3081831
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.
Feenstra MG; Sumners C; Goedemoed JH; de Vries JB; Rollema H; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(2):108-15. PubMed ID: 6646238
[TBL] [Abstract][Full Text] [Related]
9. Self-inhibitory dopamine-receptors and central effects of apomorphine.
Di Chiara G; Porceddu ML; Morelli M; Gessa GL
Ann Ist Super Sanita; 1978; 14(1):111-22. PubMed ID: 756166
[TBL] [Abstract][Full Text] [Related]
10. Effect of estrogens on dopamine autoreceptors in male rats.
Piccardi P; Bernardi F; Rossetti Z; Corsini G
Eur J Pharmacol; 1983 Jul; 91(1):1-9. PubMed ID: 6617733
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.
Imperato A; Tanda G; Frau R; Di Chiara G
J Pharmacol Exp Ther; 1988 Apr; 245(1):257-64. PubMed ID: 3258912
[TBL] [Abstract][Full Text] [Related]
12. Evidence for autoreceptor modulation of endogenous dopamine release from rabbit caudate nucleus in vitro.
Parker EM; Cubeddu LX
J Pharmacol Exp Ther; 1985 Feb; 232(2):492-500. PubMed ID: 3155797
[TBL] [Abstract][Full Text] [Related]
13. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
Gomez-Mancilla B; Boucher R; Gagnon C; Di Paolo T; Markstein R; Bédard PJ
Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480
[TBL] [Abstract][Full Text] [Related]
14. The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents.
Dolphin AC; Jenner P; Sawaya MC; Marsden CD; Testa B
J Pharm Pharmacol; 1977 Dec; 29(12):727-34. PubMed ID: 22618
[No Abstract] [Full Text] [Related]
15. Changes in the sensitivity to apomorphine of dopamine receptors modulating dopamine and acetylcholine release after chronic treatment with bromocriptine or haloperidol.
Cubeddu LX; Hoffmann IS; James MK; Niedzwiecki DM
J Pharmacol Exp Ther; 1983 Sep; 226(3):680-5. PubMed ID: 6887008
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice.
Jenkins OF; Jackson DM
Naunyn Schmiedebergs Arch Pharmacol; 1985 Oct; 331(1):7-11. PubMed ID: 3877878
[TBL] [Abstract][Full Text] [Related]
17. Evidence for dopamine receptors mediating sedation in the mouse brain.
Di Chiara G; Porceddu ML; Vargiu L; Argiolas A; Gessa GL
Nature; 1976 Dec; 264(5586):564-7. PubMed ID: 1004597
[No Abstract] [Full Text] [Related]
18. Simultaneous radioenzymatic assay of dopamine and dihydroxyphenylacetic acid: an index of in vivo dopamine release.
Cheng CH; Wooten GF
J Pharmacol Methods; 1981 Mar; 5(2):165-73. PubMed ID: 7230840
[TBL] [Abstract][Full Text] [Related]
19. Locomotor-activating effects of the D2 agonist bromocriptine show environment-specific sensitization following repeated injections.
Hoffman DC; Wise RA
Psychopharmacology (Berl); 1992; 107(2-3):277-84. PubMed ID: 1535445
[TBL] [Abstract][Full Text] [Related]
20. Experimental catalepsy is both enhanced and disrupted by apomorphine.
Klemm WR
Psychopharmacology (Berl); 1985; 87(1):12-5. PubMed ID: 3933030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
